Treatment of older adults with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) is challenging because of disease morbidity and associated treatments. Both diseases represent a genetically heterogeneous group of disorders primarily affecting older adults, with treatment strategies ranging from...
In 2014, the lifetime risks of acute myeloid leukemia (AML) in the United States will be 0.44% and 0.36% for men and women, respectively [1]. This means that 1 in 227 men and 1 in 278 women born today will be diagnosed with AML during their lifetime. AML accounts for 75-80% of...
Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse Gemtuzumab ozogamicin (CMA-676, Mylotarg, an antibody-targeted chemotherapy agent, was recently approved by the FDA for the treatment of patients with CD33... EL Sievers - 《Expert ...
Prognostic factors for intensive care unit admission, intensive care outcome, and post-intensive care survival in patients with de novo acute myeloid leukemia: a single center experience Haematologica, 96 (2011), pp. 231-237 CrossrefView in ScopusGoogle Scholar 57 C Algrin, S Faguer, V Lemial...
Acute myeloid leukemia (AML) presents in all ages but is mainly a disease of the elderly with a median age of 69 years in the white US population of the Surveillance, Epidemiology, and End Results database.1 Age has a major impact on the management and outcome for patients with AML. Eld...
Acute myeloid leukemia (AML) is a very heterogeneous and highly malignant blood cancer. Mutations of the DNA methyltransferase DNMT3A are among the most frequent recurrent genetic lesions in AML. The majority of DNMT3A-mutant AML patients shows fast rela
Acute lymphoblastic leukemia (ALL) is the commonest childhood malignancy, accounting for approximately 80% of leukemia in the pediatric group, and its etiology is unknown. This neoplasia is characterized by male predominance, high-risk features and poor outcome, mainly in recurrence patients and adul...
We evaluated the association of HDI with rates and outcomes of hematopoietic stem cell transplantation (HSCT) for patients with acute leukemia. For the analysis of HSCT rates, all adults with acute leukemia (n = 16 403) treated in 30 European countries, between 2001 and 2005, were included. ...
Most acute leukemia patients receive consecutive intensive chemotherapy, which usually takes several months before allogeneic hematopoietic stem cell transplantation (allo-HCT). Intensive chemotherapy often induces gastrointestinal adverse events. These adverse events leave patients in a state of malnutrition, ...
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453–74. Article CAS Google Scholar Download references Acknowledgements The authors would like to acknowledge and thank Lucinda ...